Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile
George Dangas, MDa,
Juan J. Badimon, PhDa,
Donald A. Smith, MDa,
Allen H. Unger, MD, FACCa,
Daniel Levine, PhD*,
John H. Shao, BSa,
Perwaiz Meraj, BSa,
Carl Fier, MDa,
John T. Fallon, MD, PhDa and
John A. Ambrose, MD, FACCa
a Cardiovascular Institute and the Departments of Medicine and Pathology, Mount Sinai School of Medicine, New York, New York, USA
* Rogosin Institute, Cornell University Medical College, New York, New York, USA
View larger version (35K):
[in a new window]
|
Figure 1 Changes of total thrombus area in the three study groups (perfusion chamber substudy). Significant changes (p < 0.04) compared to baseline are indicated by asterisk (*).
|
|
View larger version (17K):
[in a new window]
|
Figure 2 Perfusion chamber substudy (n = 40): correlation between change in LDL-cholesterol and total thrombus area after 6 months of therapy.
|
|
View larger version (27K):
[in a new window]
|
Figure 3 Perfusion chamber substudy (n = 40): baseline total thrombus formation was significantly lower (*p < 0.04) in patients receiving aspirin compared to those who were not treated with aspirin.
|
|
View larger version (30K):
[in a new window]
|
Figure 4 Perfusion chamber substudy, pravastatin-treated patients (n = 28): the decrease in total thrombus formation was significantly greater (*p < 0.04) in patients not treated with aspirin compared to those who were receiving aspirin.
|
|
|
